93414-04-1

Basic information

• Product Name: Desvenlafaxine (O-DesMethyl Venlafaxine) FuMarate
• Synonyms: Desvenlafaxine (O-DesMethyl Venlafaxine) FuMarate
• CAS NO: 93414-04-1
• Molecular Formula: C₄H₄O₄*C₁₆H₂₅NO₂
• Molecular Weight: 379.44736
• Mol File: 93414-04-1.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Desvenlafaxine (O-DesMethyl Venlafaxine) FuMarate(CAS DataBase Reference)
• NIST Chemistry Reference: Desvenlafaxine (O-DesMethyl Venlafaxine) FuMarate(93414-04-1)
• EPA Substance Registry System: Desvenlafaxine (O-DesMethyl Venlafaxine) FuMarate(93414-04-1)

Safety Data

• Hazardous Substances Data: 93414-04-1(Hazardous Substances Data)

Upstream product

• 300827-87-6 O-desvenlafaxine hydrochloride 
• 110-17-8 (2E)-but-2-enedioic acid 
• 93413-62-8 O-desmethylvenlafaxine 

Relevant articles and documents

CRYSTAL FORMS OF O-DESMETHYLVENLAFAXINE FUMARATE

Provided are crystalline forms of O-desmethylvenlafaxine fumarate, methods for their preparation, and pharmaceutical composition thereof.

A METHOD OF PREPARATION OF DESVENLAFAXINE AND ITS SALTS

A method of preparation of 4-(2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl)phenol of formula (I), known under the generic name desvenlafaxine, and its pharmaceutically acceptable salts, which comprises (a) stirring up O-benzyl desvenlafaxine or its derivative of formula (II), or its salt, where R is selected from H, 4-methyl, 4-methoxy, 3,4-dimethoxy, 2-nitro, 4-nitro, 4-chloro, 4-bromo, 2,6-dichloro and 2,6-difluoro, in an organic solvent or a mixture of organic solvents, followed by dissolution of the starting substance at pH 3 to 8; (b) transformation of O-benzyl desvenlafaxine or its derivative of formula (II) to desvenlafaxine (I) by catalytic hydrogenation; (c) removing the catalyst from the desvenlafaxine solution with the pH value of 3 to 8 by filtration, followed by increasing pH to a value higher than 8 and lower than 11 by addition of an inorganic or organic base; (d) isolation of desvenlafaxine base (I) by filtration; and (e) transformation of desvenlafaxine base (I) to a pharmaceutically acceptable salt.